Related Experiment Videos
Effect of amrinone on anthracycline-induced lethal and cardiac toxicity in mice and rats
F Villani1, C Manzotti, M Mella
1Istituto Nazionale per lo Studio e La Cura dei Tumori, Milano, Italy.
Abstract:
The protective role of amrinone against toxicity of anthracyclines was examined in both mice and rats. These two anthracyclines were selected since they are characterized by different patterns of toxicity. In contrast to doxorubicin, the 4'-deoxy derivative did not cause delayed mortality. The results of this investigation indicate that amrinone is an effective protective agent against acute lethal events induced by both anthracyclines. However, the inotropic agent did not reduce the delayed mortality produced by doxorubicin. This parallels the apparent lack of prevention of doxorubicin-induced myocardial toxicity in CD rats, as determined by ECG changes and by morphologic alterations following multiple drug administrations. The administration of amrinone did not interfere with the antitumor activity of 4'-deoxy-doxorubicin against C-26 colon tumor.
Insights
Amrinone effectively protects against acute lethal events from anthracyclines like doxorubicin. However, it does not prevent delayed mortality or myocardial toxicity associated with doxorubicin treatment.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Anthracyclines are potent chemotherapy agents with significant toxicities.
- Doxorubicin and its 4'-deoxy derivative exhibit distinct toxicity profiles.
- Amrinone is an inotropic agent with potential cardioprotective properties.
Purpose of the Study:
- To evaluate the protective efficacy of amrinone against anthracycline-induced toxicity.
- To compare the effects of amrinone on acute versus delayed mortality.
- To assess amrinone's impact on doxorubicin-induced myocardial toxicity and antitumor activity.
Main Methods:
- Animal models (mice and rats) were used to study anthracycline toxicity.
- Amrinone was administered to assess its protective role against two different anthracyclines.
- Electrocardiogram (ECG) changes and morphologic alterations were used to evaluate myocardial toxicity.
Main Results:
- Amrinone demonstrated effectiveness in preventing acute lethal events from both anthracyclines.
- Amrinone did not reduce delayed mortality caused by doxorubicin.
- No prevention of doxorubicin-induced myocardial toxicity was observed with amrinone administration.
- Amrinone did not interfere with the antitumor activity of 4'-deoxy-doxorubicin.
Conclusions:
- Amrinone offers protection against acute anthracycline toxicity but not delayed effects.
- Amrinone is not effective in preventing doxorubicin-induced myocardial toxicity.
- Amrinone preserves the antitumor efficacy of certain anthracyclines.